Patient capital
Article Abstract:
India is becoming a center for carrying out clinical trials. Computer staff, nurses and researchers cost less in India, and there is a wide range of diseases from TB amd malaria to heart disease and cancer. Infrastructure for trials has been underdeveloped, and there are concerns about bureaucracy, as well as lack of protection for pharmaceutical patents. There are also ethical problems, both over whether participants are able to give informed consent, and whether they can afford the drugs being tested. These problems are being tackled, with new guidelines being drafted.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Best of both worlds: pharmaceuticals in India
Article Abstract:
Piramal Enterprises in India has become a huge pharmaceutical company through the acquisition of the Indian division of big multinational drug companies. Piramal has been able to take advantage of the frustration these companies have gotten doing business in India.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Rites of passage
Article Abstract:
Alliances set up between pharmaceutical and biotechnology companies are examined in detail.
Publication Name: The Economist (UK)
Subject: Business, international
ISSN: 0013-0613
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Ancient and modern. The white heat of Mandelson. Inexact science
- Abstracts: Le chef. Taste buds down under. A gastronomic cluster
- Abstracts: Viagra encounters challenge. Malaysian candidates tread softly amid party's ban on campaigning. P&G picks starcom and MediaVest to replace Zenith in China account.(Procter and Gamble, Zenith Media Ltd.)
- Abstracts: America the unready. Poisoned island
- Abstracts: Re-opening. Risk's new terrorism. Tall storeys